Elicera Therapeutics

Elicera Therapeutics is a clinical-stage biotech focused on developing potent cell and gene therapies for aggressive and recurrent cancers, with a core mission to conquer solid tumors. Its foundational achievement is the patented iTANK platform, which enhances CAR T-cells to recruit the patient's own immune system, creating a multi-targeted attack. The company's strategy leverages a dual business model: advancing four internal therapeutic programs (two CAR T-cell and two oncolytic virus candidates) and generating near-term value through non-exclusive out-licensing of the iTANK technology. Recent recognition of its scientific founder as 'Cancer Researcher of the Year 2026' underscores the quality of its research foundation.

The iTANK (immunoTherapeutic Activated by Notch and Ki67) platform is a universal genetic engineering technology that enhances CAR T-cells and oncolytic viruses to recruit and activate the patient's endogenous immune system, creating a polyclonal attack against solid tumors.

Elicera competes with numerous biotechs developing next-gen CAR-T for solid tumors, using mechanisms like armored CARs or dual-targeting. iTANK's differentiation is its 'bystander effect' recruiting the endogenous immune system. In oncolytic viruses, it faces niche competitors in specific indications like NETs.